All posts by Suresh Gopalan

Welcome! You may have arrived here from my blog 'Hi-Brow Perspectives'. I have a unique background and experiences as an engineer, biotechnologist and business leader with contributions that are transformative across several sectors. My current entrepreneurial journey focuses on 'building an efficient and healthy world' through continually improving and applying AI innovations across industries combining my prior background. As CEO and Co-Founder of ReSurfX (resurfx.com & @ReSurfX), I lead the development and deliver of powerful outcomes intelligence solutions to Pharma and Healthcare, empowering the industry with data-driven insights. My other favorite activity is promoting innovation and entrepreneurship in a variety of ways. You can learn more from here (Hi-Brow Perspectives), ReSurfX website and LinkedIn.
AI Evaluation of Individuals, Artificial Intelligence, business strategy, engineering systems, Foresight Evaluation, Generative AI, Healthcare, infection transmission, insurance copay, Large Language Models, patient care, pharma enterprise, Physical, Engineering and Social Concepts, vaccines, virus

Foresight. Chest Thumps. AI Approved.

1 Comment

In this post, I use AI to evaluate, validate and showcase how a person’s predictions have been incredibly accurate and valuable in multiple fields consistently. I used information I had released in the public domain in various formats for this exercise, and used a third-person perspective  to maintain objectivity of leading commercial generative AI (GenAI) platforms used.

From Suresh_AI-Validated_v2-1
Suresh_AI-Validated_Profile

The AI evaluates me as a rare category of strategic thinker with exceptional foresight on structural viability, hidden risks, and systemic incentives of any complex enterprise—whether it is a company, a technology, a public policy, or a scientific field.  Multiple AI platforms used very similar words, phrases and sentiments to commend my foresight of immense value. Continue reading Foresight. Chest Thumps. AI Approved. →

AI Evaluation of Individuals, Artificial Intelligence, biologic drugs, Block chain technology, blockchain, business strategy, COVID-19, Cryptocurrency, GenAI, Healthcare, infection transmission, insurance copay, Internet search, knowledge extraction, patient data privacy, Physical, Engineering and Social Concepts, Social Adaptability, vaccines

A Profile in Foresight: AI Analysis of Suresh Gopalan’s Public Domain Insights

1 Comment

This content is an accompanying piece to the article “Foresight. Chest Thumps. AI Approved.” inHi-Brow Perspectives.. The main article offers a higher-level summary of the individual, while this one supplements it with more detailed evaluations of each data source reviewed. That article demonstrates the use of Generative AI to assess a person based on publicly available material of the author in an unbiased manner. In this case, GenAI evaluated Suresh Gopalan, author of this blog, and found him to be a remarkably insightful individual with exceptional foresight across multiple fields. The evaluation notes that Suresh Gopalan not only identifies correct failure points (which have played out as predicted), but also proposes possible solutions.

Suresh_AI-Validated_Details

The AI evaluates me as a rare category of strategic thinker with exceptional foresight of high value with consistent focus on systemic architecture, compounding risk, and real-world failure modes of any complex enterprise. The themes evaluated cover business, innovation, societal impact, deep-tech, deep-science, and more. Here I provide  the Evaluation Summary Table for each of the information source provided for the GenAI to analyze.

Continue reading A Profile in Foresight: AI Analysis of Suresh Gopalan’s Public Domain Insights →

biologic drugs, biosimilars, business strategy, cost of biologics, Healthcare, insurance copay, manufacturers copay programs, patient care, patient data privacy, pharma enterprise

Biologics and Biosimilar Treatment: Sell Your Data or Sell Your Kidney?

1 Comment

The pharmaceutical industry’s advancements in the development of biologics, a class of medications, have expanded the range of treatable disease conditions, but at extremely high costs and insurance copays. This post focuses on a concerning aspect of manufacturer copay programs – initiatives designed to help cover insurance copays associated with biologic treatments. Specifically, we will examine copay program agreement of Sandoz and raise concerns about patient privacy and medical information sharing.

Biosimilars - Sell Your Data or Sell Your Kidney?

Continue reading Biologics and Biosimilar Treatment: Sell Your Data or Sell Your Kidney? →

Block chain technology, blockchain, Cryptocurrency, Decentralized autonomous organizations (DAOs), Distributed digital ledgers, engineering systems, Physical, Engineering and Social Concepts, smart contract

Is Cryptocurrency Ready to Go Mainstream? Is One Answer in ‘Tomorrow Never Dies’?

1 Comment

Unless you have been living under a rock for a while, there is hardly a chance to have missed the buzz and events involving cryptocurrency. We have heard of overnight billionaires and overnight crash in value of Trillion dollars. Are we ready to adopt cryptocurrency in mainstream society? What do we need to consider besides many topics you can find if you search the internet?

Continue reading Is Cryptocurrency Ready to Go Mainstream? Is One Answer in ‘Tomorrow Never Dies’? →

airbag, COVID-19, Healthcare, infection transmission, Masks, Mutual protection, pandemic, seat belts, social distancing, Social safety, vaccines, virus

COVID-19: Applauding a powerful messaging that serves as call to action

Leave a comment

The long awaited break to end the pandemic phase of COVID-19 pandemic we all await continues to elude us despite many breakthrough control tools and measures. In times like these when participation of everyone is needed, succinct and clear messaging is a key – and we dedicate this post to applaud one powerful and succinct statement.

Applauding a COVID-19 messaging

Continue reading COVID-19: Applauding a powerful messaging that serves as call to action →

airbag, automobiles, business strategy, COVID-19, Healthcare, infection transmission, Masks, pandemic, seat belts, social distancing, Social safety, vaccines, virus

COVID-19 Vaccines: Hits, Misses, Mandates and Charting the Post-pandemic Normal

2 Comments

While we await the end of the pandemic phase of COVID-19 and to begin the new normal, we recognize the rapid development and deployment of vaccines as one of the biggest success of science, technology, regulatory flexibility. That and the rapid and effective role played by governments in many parts of the world as highlights of what we as a society can do to rise to serious challenges. These accomplishments would have been decade long process in the past or minimally a multi-year process.

Shields against COVID-19

As with the other posts of ‘HiBrow Perspectives’ – we highlight salient and some not obvious aspects of some of these huge successes in biomedical and technological innovations, business strategy, regulatory and governance aspects that have impacted the society positively in major ways as well as some stark disappointments.

Continue reading COVID-19 Vaccines: Hits, Misses, Mandates and Charting the Post-pandemic Normal →

COVID-19, Healthcare, infection transmission, Masks, pandemic, Physical, Engineering and Social Concepts, Social safety, virus

Crushing COVID-19: Masks, Messaging and Creating the Moment

3 Comments

Masks, do they protect me directly if I wear? Why should I wear them if it protects others and not me? Here I present a line of reasoning for masks being protective to the person who wears it and relate it to a rapid acting equivalent of vehicle seat belts. I hope the message in this blog aids change in mindset and practice, and together with other developments in place now help us create ‘The Moment’ to hold current state of the COVID-19 pandemic as its worst and help move to build a better future faster.

Crushing COVID-19 pandemic.

Continue reading Crushing COVID-19: Masks, Messaging and Creating the Moment →

biology, engineering practices, engineering systems, Healthcare, pharma enterprise

Did Andy Grove Leave a Fallacy for Life Sciences and Healthcare?

Leave a comment

Yes, you guessed it right.. we are talking about the Andy Grove who left an indelible legacy through his role at the Intel corporation (together with the other two founders Robert Noyce and Gordon Moore) including as CEO for a decade, fueling the growth of Silicon Valley and the world at large. Now we got that cleared, we need to introduce some background on what is called the ‘Andy Grove Fallacy’ in a commentary in 2007.

Continue reading Did Andy Grove Leave a Fallacy for Life Sciences and Healthcare? →

Artificial Intelligence, Internet search

How does AI, Waymo self-driving taxi launch and Google indicate room for another search engine?

5 Comments

In exciting news this week Waymo™ the driverless car arm of Alphabet™ (the parent company of Google) launched its fully self-driving taxi service ‘Waymo One’ in Phoenix, Arizona. There is one catch though; the self-driving taxis each have a driver in them. What can we infer from this artificial intelligence (AI) enabled initiative and other offerings from the Alphabet conglomerate? Continue reading How does AI, Waymo self-driving taxi launch and Google indicate room for another search engine? →

Healthcare

How do we prevent denial of available and deserved therapeutic options to patients?

3 Comments

I read this excellent post The Irrational Rationing of Health Care on LinkedIn by David Katz, that documents a case of denial of a treatment option to a patient because the payer considers that ‘not established as standard therapy for that cancer’ – as documented in their business criteria. As you would have guessed that the treatment option is a reasonably expensive one. This is an excellent article and an exemplary case for what I elaborate in previous blogs http://bit.ly/ACOSteadyState and http://bit.ly/sustainablehealthcare .

Continue reading How do we prevent denial of available and deserved therapeutic options to patients? →